Loading...

Infusion Therapies And Advanced Systems Will Shape Healthcare Outcomes

Published
26 May 25
Updated
27 Aug 25
AnalystConsensusTarget's Fair Value
US$176.50
30.8% undervalued intrinsic discount
04 Sep
US$122.07
Loading
1Y
-31.1%
7D
4.3%

Author's Valuation

US$176.530.8% undervalued intrinsic discount

AnalystConsensusTarget Fair Value

Shared on27 Aug 25
Fair value Decreased 3.45%

The reduction in ICU Medical’s price target reflects weaker growth expectations, as consensus revenue projections have turned negative, while a lower future P/E ratio suggests diminished earnings optimism; accordingly, the fair value estimate has decreased from $182.80 to $176.50. What's in the News ICU Medical raised its 2025 GAAP net loss guidance, now expecting a loss between $43 million and $35 million, with GAAP diluted loss per share between $1.68 and $1.38.